Focus on Lower Risk of Tardive Dyskinesia with Atypical Antipsychotics

References

• Jeste DV, Wyatt RJ: Understanding and Treating Tardive Dyskinesia. New York: Guilford Press, 1982
   Google Scholar
• Tardive Dyskinesia: A Task Force Report of the American Psychi- atric Association. Washington, DC: The American Psychiatric Association, 1992
   Google Scholar
• Kane JM, Woemer M, Borenstein M, Wegner J, Lieberman J: Integrating incidence and prevalence of tardive dyskinesia. Psy-chopharmacol Bull 1986; 22:254–258
   PubMedGoogle Scholar
• Meltzer HY: The mechanism of action of clozapine in relation to its clinical advantages. In: HY, Meltzer ed. Novel Antipsychotic Drugs. New York: Raven Press, 1992:1–13
   Google Scholar
• Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (que-tiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233–246
   Google Scholar
• Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39:473–481
   PubMed Web of Science ®Google Scholar
• Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37:1368–1373
   PubMed Web of Science ®Google Scholar
• Blowers AJ, Borison RL, Blowers CM, Bicknell DJ: Abnormal involuntary movements in the elderly. Br J Psychiatry 1981; 139:363–364
   Google Scholar
• Molsa PK, Martilla RI, Rinne UK: Extrapyramidal symptoms in dementia. Neurology 1984; 34:1114–1116
   PubMed Web of Science ®Google Scholar
• Jeste DV, Caligiuri MP, Paulsen JS, et al.: Risk of tardive dyskine-sia in older patients. A prospective longitudinal study of 266 out-patients. Arch Gen Psychiatry 1995; 52: 756–765
   Google Scholar
• Woemer MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM: Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998; 155:1521–1528
   Google Scholar
• Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157:1150–1155
   PubMedGoogle Scholar
• Jeste DV: Low TD rate with quetiapine in the elderly. Paper presented at Philadelphia, PA Institute for Psychiatric Services, October 25–29,2000
   Google Scholar
• Campbell M, Grega DM, Green WH, Bennett WG: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 1983; 6:207–222
   Google Scholar
• Polizos P. Engelhardt DM, Hoffman SP, Waizer J: Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr 1973; 3:247–253
   PubMedGoogle Scholar
• Engelhardt DM, Polizos P. Waizer J: CNS consequences of psychotropic drug withdrawal in autistic children: A follow-up report. Psychopharmacol Bull 1975; 11:6–7
   PubMedGoogle Scholar
• Smith JM, Dunn DD: Sex differences in the prevalence of severe tardive dyskinesia. Am J Psychiatry 1979; 136:1080–1082
   PubMedGoogle Scholar
• Hruska RE: Sex hormone exposure and non-reproductive behav-ior. Int J Ment Health 1985; 14:112–134
   Web of Science ®Google Scholar
• Richardson MA, Pass R, Craig TJ, Vickers E: Factors influencing the prevalence and severity of tardive dyskinesia. Psychopharma-col Bull 1984; 20:33–38
   PubMed Web of Science ®Google Scholar
• Kalow W: Pharmacogenetics of Drug Metabolism. New York: Pergamon, 1992
   Google Scholar
• Webber WW: Pharmacogenetics. New York: Oxford University Press, 1997
   Google Scholar
• Lin K-M, Poland RE: Ethnicity, culture, and psychopharmacology. In: FE, Bloom, DI, Kupfer eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995:1907–1917
   Google Scholar
• Daly AK, Brockmoller J, Broly F, et al.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193–201
   Google Scholar
• Morgenstern H, Glazer WM: Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuro-leptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993; 50:723–733
   PubMed Web of Science ®Google Scholar
• Glazer WM, Morgenstern H, Doucette J: Race and tardive dyski-nesia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45:38–42
   Google Scholar
• Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K: Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 1997; 9:53–55
   Google Scholar
• Littlewood R: Psychiatric diagnosis and racial bias: empirical and interpretative approaches. Soc Sci Med 1992; 34:141–149
   PubMed Web of Science ®Google Scholar
• Lawson WB: Issues in pharmacotherapy for African Americans. In: P, Ruiz ed. Ethnicity and Psychopharmacology. Washington, DC: American Psychiatric Press, 2000:37–53
   Google Scholar
• Lin KM, Finder E: Neuroleptic dosage for Asians. Am J Psychia-try 1983; 140:490–491
   PubMed Web of Science ®Google Scholar
• Ruiz S, Chu P. Sramek J, Rotavu E, Herrera J: Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996; 63:306–309
   PubMedGoogle Scholar
• Sramek JJ, Sayles MA, Simpson GM: Neuroleptic dosage for Asians: A failure to replicate. Am J Psychiatry 1986; 143:535–536
   PubMed Web of Science ®Google Scholar
• Davis KL, Berger PA, Hollister LE: Tardive dyskinesia and depressive illness. Psychopharmacol Commun 1976; 2:125–130
   PubMedGoogle Scholar
• Mulcheijee S, Rosen AM, Caracci G, Shulda S: Persistent tardive dys-kinesia in bipolar patients. Arch Gen Psychiatry 1986; 43:342–346
   Google Scholar
• Casey DE: Affective disorders and tardive dyskinesia. Encep hale 1988; 14:221–226
   Google Scholar
• Nasrallah HA, Churchill CM, Hamdan-Allan GA: Higher fre-quency of neuroleptic-induced dystonia in mania than in schizo-phrenia. Am J Psychiatry 1988; 145:1455–1456
   PubMed Web of Science ®Google Scholar
• Wegner if, Catalano F, Gibralter J, Kane JM: Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry 1985; 42:860–865
   Google Scholar
• Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J: Integrating incidence and prevalence of tardive dyskinesia. Psy-chopharmacol Bull 1986; 22:254–258
   PubMedGoogle Scholar
• Barnes TRE, Lidclle PF: Tardive dyskinesia: Implications for schizophrenia? In: AA, Schiff, M, Roth, HL, Freeman eds. Schizophrenia: New Pharmacological and Clinical Development. London: Royal Society of Medicine Services, 1985:81–87
   Google Scholar
• Owens DG, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement: Their prevalence, severity, and distribu-tion in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982; 39:452–461
   PubMedGoogle Scholar
• Waddington IL, Youssef HA: Late onset involuntary movements in chronic schizophrenia: Relationship of "tardive" dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry 1986; 149:616–620
   PubMed Web of Science ®Google Scholar
• Yassa R, Nair V, Schwartz G: Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25:135–138
   PubMed Web of Science ®Google Scholar
• Woemer MG, Saltz BL, Kane JM, Lieberman JA, Alvir JM: Dia-betes and development of tardive dyskinesia. Am J Psychiatry 1993; 150:966–968
   Google Scholar
• American Diabetes Association; American Psychiatric Associa-tion; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus devel-opment conference on antipsychotic drugs and obesity and diabe-tes. Diabetes Care 2004; 27:596–601
   Google Scholar
• Waddington IL: Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int Rev Neurobiol 1989; 31:297–353
   PubMedGoogle Scholar
• Christensen E, Moller JE, Faurbye A: Neuropathological investi-gation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970; 46:14–23
   PubMed Web of Science ®Google Scholar
• Campbell WG, Raskind MA, Gordon T, Shaw CM: Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry 1985; 142:364–365
   PubMed Web of Science ®Google Scholar
• Arai N, Amano N, Iseld E, et al.: Tardive dyskinesia with inflated neurons of the cerebellar dentate nucleus. Case reports and morpho-metric study. Acta Neuropathol (Berl) 1987; 73:38–42
   Google Scholar
• Saltz BL, Woemer MG, Kane JM, et al.: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402–2406
   Google Scholar
• American College of Neuropsychopharmacology - Food and Drug Administration Task Force: Schiele BC, Gallant D, Simpson G, et al.: Neurologic syndromes associated with antipsychotic-drug use. N Engl J Med 1973; 289:20–23
   Google Scholar
• Goldman MB, Luchins DJ: Intermittent neuroleptic therapy and tardive dyskinesia: A literature review. Hosp Community Psychi-atry 1984; 35:1215–1219
   PubMedGoogle Scholar
• Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore P: The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988; 8:31S–37S
   Google Scholar
• Carpenter WT Jr, Heinrichs DW, Hanlon TE: A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144:1466–1470
   Google Scholar
• Klawans HL, Rubovits R: Effect of cholinergic and anticholin-ergic agents on tardive dyskinesia. J Neurol Neurosurg Psych 1974; 37:941–947
   PubMedGoogle Scholar
• Jus A, Gautier J, Villeneuve A, et al.: Chronology of combined neuroleptics and antiparkinsonian administration. Am J Psychia-try 1977; 134:1157
   Google Scholar
• Greil W, Haag H, Rossnagl G, Ruther E: Effect of anticholin-ergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984; 145:304–310
   Google Scholar
• Klawans HL, Goetz CG, Perlik S: Tardive dyskinesia: Review and update. Am J Psychiatry 1980; 137:900–908
   PubMed Web of Science ®Google Scholar
• Gardos G, Cole JO: Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1983; 140:200–202
   PubMed Web of Science ®Google Scholar
• Pert A, Rosenblatt JE, Sivit C, Pert CB, Bunney WE Jr.: Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978; 201:171–173
   Google Scholar
• Barnes TR, Kidger T, Gore SM: Tardive dyskinesia: A 3-year fol-low-up study. Psychol Med 1983; 13:71–81
   PubMed Web of Science ®Google Scholar
• Casey DE: Side effects of new antipsychotic agents. J Clin Psy-chiatry 1996; 57:40–45
   Google Scholar
• Kane JM: Extrapyramidal side effects are unacceptable. Eur Neu-ropsychopharmacol 2001; 11\(suppl 4):5397–5403
   Google Scholar
• Gerlach J: Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychia-try 2002; 14:47–57
   PubMedGoogle Scholar
• Friedman JH: Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003; 28\(suppl 1):39–51
   Google Scholar
• Dolder CR, Jeste DV: Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psy-chiatry 2003; 53:1142–1145
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004; 161:414–425
   PubMed Web of Science ®Google Scholar